A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Pancreatic Adenocarcinoma · Resectable Pancreatic Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Study coordinator (Barbara Kleiber, MACPR, BSN, RN) · 614-293-1815
Contact: Principal Investigator (Ashish Manne, MBBS)

Study leads

Ashish Manne, MD
Principal Investigator
The Ohio State University Comprehensive Cancer Center- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

Pancreatic Cancer · Pancreatic Adenocarcinoma · Metastatic Pancreatic Cancer

IsraelRecruiting

Gilbert, United States · Goodyear, United States

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Metastatic Pancreatic Adenocarcinoma · Recurrent Pancreatic Adenocarcinoma · Stage IV Pancreatic Cancer AJCC v8

Abroad (travel likely)RecruitingPHASE2

Scottsdale, United States · Jacksonville, United States

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Ductal Adenocarcinoma · Resectable Pancreatic Adenocarcinoma · Stage I Pancreatic Cancer AJCC v8

Abroad (travel likely)RecruitingPHASE2

Atlanta, United States

Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Beijing, China